The startup has developed a non-invasive prenatal diagnosis technology that isolates fetal nucleated red blood cells from maternal blood using laminated microfluidic devices for massive cell fractionation. This technology enables early and definitive diagnosis of fetal chromosomal disorders, ensuring safer pregnancies for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods for prenatal diagnosis of fetal chromosomal disorders, such as amniocentesis and chorionic villus sampling, are invasive and carry risks for both the mother and the fetus. Obtaining fetal cells for genetic analysis typically requires invasive procedures, posing potential complications and limiting the accessibility of early diagnosis.
Solution
TL Genomics provides a non-invasive prenatal testing (NIPT) solution using microfluidic devices to isolate fetal nucleated red blood cells (fNRBCs) from maternal blood. The company's laminated microfluidic devices enable massive cell fractionation, allowing for the enrichment of rare fetal cells without the need for pre-treatment steps like hemolysis or centrifugation. The isolated fNRBCs can then be used for downstream genetic analysis, providing early and definitive diagnosis of fetal chromosomal disorders with reduced risk compared to traditional invasive methods. TL Genomics leverages its proprietary SinChro™ technology, a PCR-based method, to accurately count chromosomes from a small number of cells.
Target Audience
The primary target audience includes expectant parents seeking early and non-invasive prenatal diagnosis, as well as clinicians and researchers in the fields of reproductive health, genetics, and oncology.
Features
- Laminated microfluidic devices for high-throughput cell fractionation and enrichment of fNRBCs
- No pre-treatment of blood samples required, simplifying the workflow
- Anti-clogging technology enabling continuous blood sample processing
- SinChro™ technology for sensitive and accurate chromosomal copy number analysis from single cells
- Detection of chromosomal abnormalities associated with diseases like myelodysplastic syndromes
- Application of microfluidic devices for isolating tumor-infiltrating lymphocytes (TILs) from tumor tissues
- Development of in-vitro diagnostics for bone marrow transplantation
- MyAge and MyAgeF, are services that measure the rate of sex chromosome loss to understand the degree of aging.